AorTech International PLC Posting of Report & Accounts and Notice of Meeting (9283H)
August 05 2019 - 8:36AM
UK Regulatory
TIDMAOR
RNS Number : 9283H
AorTech International PLC
05 August 2019
5 August 2019
AorTech International plc
("AorTech", the "Company" or the "Group")
Posting of Report & Accounts
and
Notice of Meeting
AorTech International plc (AIM: AOR), the biomaterials IP and
medical device development company, announces that its Annual
Report and Accounts for the year ended 31 March 2019, have been
posted to shareholders and are available on the Company's website
at
https://www.aortech.net/wp-content/uploads/2019/07/Aortech-Annual-Report-July-2019.pdf.
The Annual General Meeting will be held on Monday 19 August 2019
at 11.00 a.m. at the offices of Davidson Chalmers Stewart LLP at
163 Bath Street Glasgow G2 4SQ.
For further information contact:
AorTech International plc Tel: +44 (0)7730 718296
Bill Brown, Executive Chairman
Shore Capital Tel: +44 (0)20 7408 4050
Tom Griffiths / David Coaten
About AorTech:
AorTech has developed biostable, implantable polymers, including
Elast-Eon(TM) and ECSil(TM) the world's leading long-term
implantable co-polymers, now manufactured on its behalf by
Biomerics LLC in Utah, USA. Elast-Eon(TM) and ECSil(TM)'s
biostability is comparable to silicone while exhibiting excellent
mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic
extrusion and moulding techniques. With over 6 million implants and
over 10 years of successful clinical use AorTech polymers are
proven in long term life enabling applications.
In addition to continuing to exploit AorTech's Intellectual
Property related to the world class biomaterial -
Elast-Eon(TM), AorTech is now incorporating this material into a
number of medical devices of our own design. Elast-Eon(TM) has
first class long term blood contacting properties and as a result,
all of the initial products being developed are for the cardio
vascular field. Each device is being designed to have improved
clinical outcomes over current device technology,eliminating the
use of animal sourced material whilst allowing procedures to remain
the same, therefore avoiding the need of having to retrain surgeons
in new ways of operating.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSFMGGRZKZGLZM
(END) Dow Jones Newswires
August 05, 2019 08:36 ET (12:36 GMT)
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Apr 2023 to Apr 2024